![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: BTNL9 |
Gene summary for BTNL9 |
![]() |
Gene information | Species | Human | Gene symbol | BTNL9 | Gene ID | 153579 |
Gene name | butyrophilin like 9 | |
Gene Alias | BTN3 | |
Cytomap | 5q35.3 | |
Gene Type | protein-coding | GO ID | GO:0001816 | UniProtAcc | Q6UXG8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
153579 | BTNL9 | C38 | Human | Oral cavity | OSCC | 1.12e-18 | 1.40e+00 | 0.172 |
153579 | BTNL9 | C43 | Human | Oral cavity | OSCC | 6.35e-26 | 4.54e-01 | 0.1704 |
153579 | BTNL9 | C46 | Human | Oral cavity | OSCC | 2.77e-43 | 9.00e-01 | 0.1673 |
153579 | BTNL9 | LN38 | Human | Oral cavity | OSCC | 2.78e-08 | 8.96e-01 | 0.168 |
153579 | BTNL9 | LN46 | Human | Oral cavity | OSCC | 3.26e-50 | 1.58e+00 | 0.1666 |
153579 | BTNL9 | SYSMH1 | Human | Oral cavity | OSCC | 7.87e-03 | 9.95e-02 | 0.1127 |
153579 | BTNL9 | SYSMH3 | Human | Oral cavity | OSCC | 4.24e-06 | 1.47e-01 | 0.2442 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
GO:00027646 | Oral cavity | OSCC | immune response-regulating signaling pathway | 212/7305 | 468/18723 | 2.93e-03 | 1.27e-02 | 212 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
BTNL9 | SNV | Missense_Mutation | c.1328N>A | p.Arg443His | p.R443H | Q6UXG8 | protein_coding | tolerated(0.08) | benign(0.052) | TCGA-B6-A0RN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
BTNL9 | SNV | Missense_Mutation | c.295G>A | p.Ala99Thr | p.A99T | Q6UXG8 | protein_coding | deleterious(0.01) | benign(0.062) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
BTNL9 | SNV | Missense_Mutation | rs375394652 | c.97G>A | p.Glu33Lys | p.E33K | Q6UXG8 | protein_coding | tolerated(0.54) | benign(0.017) | TCGA-BH-A18S-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
BTNL9 | SNV | Missense_Mutation | novel | c.492N>G | p.Phe164Leu | p.F164L | Q6UXG8 | protein_coding | deleterious(0.02) | benign(0.007) | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
BTNL9 | SNV | Missense_Mutation | c.560N>C | p.Arg187Thr | p.R187T | Q6UXG8 | protein_coding | tolerated(0.06) | benign(0.403) | TCGA-EW-A1J5-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
BTNL9 | insertion | Nonsense_Mutation | novel | c.468_469insTAG | p.Asp156_Pro157insTer | p.D156_P157ins* | Q6UXG8 | protein_coding | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
BTNL9 | insertion | In_Frame_Ins | novel | c.469_470insAAAATTTCAAAAGCT | p.Pro157delinsGlnAsnPheLysSerSer | p.P157delinsQNFKSS | Q6UXG8 | protein_coding | TCGA-A8-A07B-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
BTNL9 | insertion | Nonsense_Mutation | novel | c.682_683insAAGCTGTCTTATACTATGTTAGTGGAATTCAAAGTTGGAAAGCTC | p.Ser228delinsTer | p.S228delins* | Q6UXG8 | protein_coding | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD | ||
BTNL9 | insertion | Frame_Shift_Ins | novel | c.1511_1512insA | p.Leu505AlafsTer4 | p.L505Afs*4 | Q6UXG8 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | ||
BTNL9 | insertion | Frame_Shift_Ins | novel | c.1513dupC | p.Leu505ProfsTer4 | p.L505Pfs*4 | Q6UXG8 | protein_coding | TCGA-DS-A1OD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |